155 related articles for article (PubMed ID: 37992763)
21. dsRNA Binding Domain of PKR Is Proteolytically Released by Enterovirus A71 to Facilitate Viral Replication.
Chang YH; Lau KS; Kuo RL; Horng JT
Front Cell Infect Microbiol; 2017; 7():284. PubMed ID: 28702377
[TBL] [Abstract][Full Text] [Related]
22. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
[TBL] [Abstract][Full Text] [Related]
23. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Jiang H; Zhang Z; Rao Q; Wang X; Wang M; Du T; Tang J; Long S; Zhang J; Luo J; Pan Y; Chen J; Ma J; Liu X; Fan M; Zhang T; Sun Q
Emerg Microbes Infect; 2021 Dec; 10(1):619-628. PubMed ID: 33682641
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China.
Cai K; Wang Y; Guo Z; Yu H; Li H; Zhang L; Xu S; Zhang Q
BMC Infect Dis; 2019 Mar; 19(1):285. PubMed ID: 30917800
[TBL] [Abstract][Full Text] [Related]
25. Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71.
Lai J; Li Z; Pan L; Huang Y; Zhou Z; Ma C; Guo J; Xu L
Arch Virol; 2023 Sep; 168(10):260. PubMed ID: 37773227
[TBL] [Abstract][Full Text] [Related]
26. The internal ribosome entry site determines the neurotropic potential of enterovirus A71.
Wu GH; Lee KM; Kao CY; Shih SR
Microbes Infect; 2023 Jun; 25(5):105107. PubMed ID: 36708870
[TBL] [Abstract][Full Text] [Related]
27. Phylodynamics of Enterovirus A71-Associated Hand, Foot, and Mouth Disease in Viet Nam.
Geoghegan JL; Tan le V; Kühnert D; Halpin RA; Lin X; Simenauer A; Akopov A; Das SR; Stockwell TB; Shrivastava S; Ngoc NM; Uyen le TT; Tuyen NT; Thanh TT; Hang VT; Qui PT; Hung NT; Khanh TH; Thinh le Q; Nhan le NT; Van HM; Viet do C; Tuan HM; Viet HL; Hien TT; Chau NV; Thwaites G; Grenfell BT; Stadler T; Wentworth DE; Holmes EC; Van Doorn HR
J Virol; 2015 Sep; 89(17):8871-9. PubMed ID: 26085170
[TBL] [Abstract][Full Text] [Related]
28. Advances in anti-EV-A71 drug development research.
Wang S; Pang Z; Fan H; Tong Y
J Adv Res; 2024 Feb; 56():137-156. PubMed ID: 37001813
[TBL] [Abstract][Full Text] [Related]
29. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.
Meng T; Wong SM; Chua KB
J Virol; 2021 Oct; 95(22):e0105521. PubMed ID: 34468173
[TBL] [Abstract][Full Text] [Related]
30. The Upf1 protein restricts EV-A71 viral replication.
Xu P; Tong W; Kuo CY; Chen HH; Wang RYL
Microbes Infect; 2023; 25(8):105220. PubMed ID: 37734533
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA 876-5p modulates EV-A71 replication through downregulation of host antiviral factors.
Xu P; Xu H; Cheng HS; Chan HH; Wang RYL
Virol J; 2020 Feb; 17(1):21. PubMed ID: 32024541
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 14S-(2'-chloro-4'-nitrophenoxy)-8R/S,17-epoxy andrographolide as EV-A71 infection inhibitor.
Dai K; Tan JK; Qian W; Lee RCH; Hann Chu JJ; Zhou GC
Biochem Pharmacol; 2021 Dec; 194():114820. PubMed ID: 34748818
[TBL] [Abstract][Full Text] [Related]
33. Characterization of G-Quadruplexes in Enterovirus A71 Genome and Their Interaction with G-Quadruplex Ligands.
Lv L; Zhang L
Microbiol Spectr; 2022 Jun; 10(3):e0046022. PubMed ID: 35446122
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome of human neuroblastoma SH-SY5Y cells in response to 2B protein of enterovirus-A71.
Suanpan K; Srimanote P; Tongtawe P; Khantisitthiporn O; Supasorn O; Rattanakomol P; Thanongsaksrikul J
Sci Rep; 2022 Feb; 12(1):1765. PubMed ID: 35110649
[TBL] [Abstract][Full Text] [Related]
35. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo.
Zeng S; Meng X; Huang Q; Lei N; Zeng L; Jiang X; Guo X
Int J Antimicrob Agents; 2019 Apr; 53(4):362-369. PubMed ID: 30599241
[TBL] [Abstract][Full Text] [Related]
36. An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection.
Cheng YW; Chuang YC; Huang SW; Liu CC; Wang JR
J Biomed Sci; 2022 Feb; 29(1):10. PubMed ID: 35130884
[TBL] [Abstract][Full Text] [Related]
37. Virulence of Enterovirus A71 Fluctuates Depending on the Phylogenetic Clade Formed in the Epidemic Year and Epidemic Region.
Kobayashi K; Nishimura H; Mizuta K; Nishizawa T; Chu ST; Ichimura H; Koike S
J Virol; 2021 Nov; 95(23):e0151521. PubMed ID: 34523967
[TBL] [Abstract][Full Text] [Related]
38. TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection.
Amrun SN; Tan JJL; Rickett NY; Cox JA; Lee B; Griffiths MJ; Solomon T; Perera D; Ooi MH; Hiscox JA; Ng LFP
Sci Rep; 2020 Mar; 10(1):3810. PubMed ID: 32123257
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Neutralizing Antibody Response Kinetics in Patients with Hand, Foot, and Mouth Disease Caused by Coxsackievirus A16 or Enterovirus A71: A Longitudinal Cohort Study of Chinese Children, 2017-2019.
Zhou Y; Zhou J; Yang J; Qiu Q; Wang L; Yang J; Li Y; Liang L; Cui P; Cheng Y; Zheng W; Shi H; Gong H; Wang K; Zhou C; Chu JJH; Yu H
J Immunol; 2022 Jul; 209(2):280-287. PubMed ID: 35777850
[TBL] [Abstract][Full Text] [Related]
40. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: a descriptive study.
Duan X; Zhang C; Wang X; Ren X; Peng H; Tang X; Zhang L; Chen Z; Ye Y; Zheng M; Zhong W; Chen X; Zeng Y; Yuan P; Long L
Emerg Microbes Infect; 2022 Dec; 11(1):2510-2519. PubMed ID: 36103331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
